A Randomized, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Sintilimab Combined With Ramucirumab as Compared to Chemotherapy for the First-line Treatment of Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (ORIENT-106)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 06 Mar 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ramucirumab (Primary) ; Sintilimab (Primary) ; Capecitabine; Cisplatin; Fluorouracil; Oxaliplatin
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ORIENT-106
Sponsors Innovent Biologics

Most Recent Events

28 Feb 2023 Status changed from active, no longer recruiting to discontinued.
10 Oct 2022 Status changed from recruiting to active, no longer recruiting.
10 Oct 2022 Planned End Date changed from 31 Mar 2025 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight